Uncategorized
Orthofix International Announces 1st Quarter 2009 Results And Additional Debt Payment Ahead of Scheduled Maturity
> Q109 sales totaled $129.0 million, up 1% from reported Q108 sales and up 5% on a constant currency basis
> Sales of spinal implants were $28.8 million, down 1% vs. prior year, up 2% sequentially from Q408
> Consolidated gross margin was 74.6%, up 130 basis points from Q108
EBITDA, as defined in the Company’s credit agreement, was $21.3 million
> Q109 reported net income was $0.17 per diluted share; excluding certain items, adjusted net income was $0.35 per diluted share
> The Company made an additional $3 million debt payment ahead of scheduled maturity
> Limited market release of Trinity(R) Evolution(TM) commenced as of May 1st